1. Kang MJ, Won YJ, Lee JJ, Jung KW, Kim HJ, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and
prevalence in 2019. Cancer Res Treat. 2022; 54(2):330–344. DOI:
10.4143/crt.2022.128. PMID:
35313102. PMCID:
PMC9016309.
Article
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence
and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3):209–249. DOI:
10.3322/caac.21660. PMID:
33538338.
Article
3. Nam S, Kim D, Jung K, Choi YJ, Kang JG. Analysis of the incidence and clinical features of colorectal
nonadenocarcinoma in Korea: a national cancer registry-based
study. Ann Coloproctol. 2020; 36(6):390–397. DOI:
10.3393/ac.2020.05.03.2. PMID:
33486908. PMCID:
PMC7837402.
Article
5. Siegel RL, Miller KD, Sauer AG, Fedewa SA, Butterly LF, Anderson JC, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020; 70(3):145–164. DOI:
10.3322/caac.21601. PMID:
32133645.
Article
6. Shaukat A, Kahi CJ, Burke CA, Rabeneck L, Sauer BG, Rex DK. ACG clinical guidelines: colorectal cancer screening
2021. Am J Gastroenterol. 2021; 116(3):458–479. DOI:
10.14309/ajg.0000000000001122. PMID:
33657038.
Article
7. Sohn DK, Kim MJ, Park Y, Suh M, Shin A, Lee HY, et al. The Korean guideline for colorectal cancer
screening. J Korean Med Assoc. 2015; 58(5):420–432. DOI:
10.5124/jkma.2015.58.5.420.
Article
8. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME. Fecal DNA versus fecal occult blood for colorectal-cancer
screening in an average-risk population. N Engl J Med. 2004; 351(26):2704–2714. DOI:
10.1056/NEJMoa033403. PMID:
15616205.
Article
9. Alhadi SC, Zain WZW, Zahari Z, Hashim MNM, Aziz SHSA, Zakaria Z, et al. The use of M2-pyruvate kinase as a stool biomarker for detection
of colorectal cancer in tertiary teaching hospital: a comparative
study. Ann Coloproctol. 2020; 36(6):409–414. DOI:
10.3393/ac.2020.08.27. PMID:
32972105. PMCID:
PMC7837393.
Article
10. Han YD, Oh TJ, Chung TH, Jang HW, Kim YN, An S, et al. Early detection of colorectal cancer based on presence of
methylated syndecan-2 (SDC2) in stool DNA. Clin Epigenetics. 2019; 11(1):51. DOI:
10.1186/s13148-019-0642-0. PMID:
30876480. PMCID:
PMC6419806.
11. Meester RGS, Peterse EFP, Knudsen AB, de Weerdt AC, Chen JC, Lietz AP, et al. Optimizing colorectal cancer screening by race and sex:
microsimulation analysis II to inform the American Cancer Society colorectal
cancer screening guideline. Cancer. 2018; 124(14):2974–2985. DOI:
10.1002/cncr.31542. PMID:
29846942. PMCID:
PMC6055229.
Article
12. Liang PS, Allison J, Ladabaum U, Martinez ME, Murphy CC, Schoen RE, et al. Potential intended and unintended consequences of recommending
initiation of colorectal cancer screening at age 45 years. Gastroenterology. 2018; 155(4):950–954. DOI:
10.1053/j.gastro.2018.08.019. PMID:
30138614.
Article
13. Mannucci A, Zuppardo RA, Rosati R, Leo MD, Perea J, Cavestro GM. Colorectal cancer screening from 45 years of age: thesis,
antithesis and synthesis. World J Gastroenterol. 2019; 25(21):2565–2580. DOI:
10.3748/wjg.v25.i21.2565. PMID:
31210710. PMCID:
PMC6558439.
Article
14. Imperiale TF, Kahi CJ, Rex DK. Lowering the starting age for colorectal cancer screening to 45
years: who will come… and should they? Clin Gastroenterol Hepatol. 2018; 16(10):1541–1544. DOI:
10.1016/j.cgh.2018.08.023. PMID:
30114484.
Article
15. US Preventive Services Task Force. Screening for colorectal cancer US preventive services task force
recommendation statement. J Am Med Assoc. 2021; 325(19):1965–1977. DOI:
10.1001/jama.2021.6238. PMID:
34003218.
17. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al. Trends in long-term survival following liver resection for
hepatic colorectal metastases. Ann Surg. 2002; 235(6):759–766. DOI:
10.1097/00000658-200206000-00002. PMID:
12035031. PMCID:
PMC1422504.
Article
18. Torky R, Alessa M, Kim HS, Sakr A, Zakarneh E, Sauri F, et al. Characteristics of patients presented with metastases during or
after completion of chemoradiation therapy for locally advanced rectal
cancer: a case series. Ann Coloproctol. 2021; 37(3):186–191. DOI:
10.3393/ac.2020.08.10.1. PMID:
32972094. PMCID:
PMC8273715.
19. Ruers T, Punt C, Van Coevorden F, Pierie JPEN, Borel-Rinkes I, Ledermann JA, et al. Radiofrequency ablation combined with systemic treatment versus
systemic treatment alone in patients with non-resectable colorectal liver
metastases: a randomized EORTC Intergroup phase II study (EORTC
40004). Ann Oncol. 2012; 23(10):2619–2626. DOI:
10.1093/annonc/mds053. PMID:
22431703. PMCID:
PMC3457746.
Article
21. Sheikh S, Chen H, Sahgal A, Poon I, Erler D, Badellino S, et al. An analysis of a large multi-institutional database reveals
important associations between treatment parameters and clinical outcomes
for stereotactic body radiotherapy (SBRT) of oligometastatic colorectal
cancer. Radiother Oncol. 2022; 167:187–194. DOI:
10.1016/j.radonc.2021.12.018. PMID:
34952002.
Article
22. Nakamura Y, Hokuto D, Koyama F, Matsuo Y, Nomi T, Yoshikawa T, et al. The prognosis and recurrence pattern of right- and left-sided
colon cancer in stage II, stage III, and liver metastasis after curative
resection. Ann Coloproctol. 2021; 37(5):326–336. DOI:
10.3393/ac.2020.09.14. PMID:
32972100. PMCID:
PMC8566149.
Article
23. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al. Trends in long-term survival following liver resection for
hepatic colorectal metastases. Ann Surg. 2002; 235(6):759–766. DOI:
10.1097/00000658-200206000-00002. PMID:
12035031. PMCID:
PMC1422504.
Article
24. Park SH, Shin JK, Lee WY, Yun SH, Cho YB, Huh JW, et al. Clinical outcomes of neoadjuvant chemotherapy in colorectal
cancer patients with synchronous resectable liver ketastasis: a propensity
score matching analysis. Ann Coloproctol. 2021; 37(4):244–252. DOI:
10.3393/ac.2020.00710.0101. PMID:
34182620. PMCID:
PMC8391040.
Article
25. Sandström P, Røsok BI, Sparrelid E, Larsen PN, Larsson AL, Lindell G, et al. ALPPS improves resectability compared with conventional two-stage
hepatectomy in patients with advanced colorectal liver metastasis: results
from a Scandinavian multicenter randomized controlled trial (LIGRO
trial). Ann Surg. 2018; 267(5):833–840. DOI:
10.1097/SLA.0000000000002511. PMID:
28902669. PMCID:
PMC5916470.
Article
26. Hasselgren K, Røsok BI, Larsen PN, Sparrelid E, Lindell G, Schultz NA, et al. ALPPS improves survival compared with TSH in patients affected of
CRLM: survival analysis from the randomized controlled trial
LIGRO. Ann Surg. 2021; 273(3):442–448. DOI:
10.1097/SLA.0000000000003701. PMID:
32049675.
27. Vallance AE, van der Meulen J, Kuryba A, Charman SC, Botterill ID, Prasad KR, et al. The timing of liver resection in patients with colorectal cancer
and synchronous liver metastases: a population-based study of current
practice and survival. Colorectal Dis. 2018; 20(6):486–495. DOI:
10.1111/codi.14019. PMID:
29338108.
Article
28. Slesser AAP, Simillis C, Goldin R, Brown G, Mudan S, Tekkis PP. A meta-analysis comparing simultaneous versus delayed resections
in patients with synchronous colorectal liver metastases. Surg Oncol. 2013; 22(1):36–47. DOI:
10.1016/j.suronc.2012.11.002. PMID:
23253399.
Article
29. Brouquet A, Mortenson MM, Vauthey JN, Rodriguez-Bigas MA, Overman MJ, Chang GJ, et al. Surgical strategies for synchronous colorectal liver metastases
in 156 consecutive patients: classic, combined or reverse
strategy? J Am Coll Surg. 2010; 210(6):934–941. DOI:
10.1016/j.jamcollsurg.2010.02.039. PMID:
20510802.
Article
30. Kim JY, Park IJ, Kim HR, Kim DK, Lee JL, Yoon YS, et al. Post-pulmonary metastasectomy prognosis after curative resection
for colorectal cancer. Oncotarget. 2017; 8:36566–36577. DOI:
10.18632/oncotarget.16616. PMID:
28402263. PMCID:
PMC5482677.
Article
31. Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal
cancer: a systematic review of published series. Ann Thorac Surg. 2007; 84(1):324–338. DOI:
10.1016/j.athoracsur.2007.02.093. PMID:
17588454.
Article
32. Meng D, Fu L, Wang L, Dai Y, Lv W, Zhang J, et al. Video-assisted thoracoscopic surgery versus open thoracotomy in
pulmonary metastasectomy: a meta-analysis of observational
studies. Interact Cardiovasc Thorac Surg. 2016; 22(2):200–206. DOI:
10.1093/icvts/ivv309. PMID:
26590306.
Article
33. Mitry E, Guiu B, Cosconea S, Jooste V, Faivre J, Bouvier AM. Epidemiology, management and prognosis of colorectal cancer with
lung metastases: a 30-year population-based study. Gut. 2010; 59(10):1383–1388. DOI:
10.1136/gut.2010.211557. PMID:
20732912.
Article
34. Roh SJ, Park SC, Choi J, Lee JS, Lee DW, Hong CW, et al. Cytoreductive surgery and hyperthermic intraperitoneal
chemotherapy with mitomycin C used for colorectal peritoneal
carcinomatosis. Ann Coloproctol. 2020; 36(1):22–29. DOI:
10.3393/ac.2019.04.30. PMID:
32146785. PMCID:
PMC7069674.
Article
35. Goéré D, Glehen O, Quenet F, Guilloit JM, Bereder JM, Lorimier G, et al. Second-look surgery plus hyperthermic intraperitoneal
chemotherapy versus surveillance in patients at high risk of developing
colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised,
phase 3 study. Lancet Oncol. 2020; 21(9):1147–1154. DOI:
10.1016/S1470-2045(20)30322-3.
Article
36. Klaver CEL, Wisselink DD, Punt CJA, Snaebjornsson P, Crezee J, Aalbers AGJ, et al. Adjuvant hyperthermic intraperitoneal chemotherapy in patients
with locally advanced colon cancer (COLOPEC): a multicentre, open-label,
randomised trial. Lancet Gastroenterol Hepatol. 2019; 4(10):761–770. DOI:
10.1016/S2468-1253(19)30239-0.
37. Quénet F, Elias D, Roca L, Goéré D, Ghouti L, Pocard M, et al. Cytoreductive surgery plus hyperthermic intraperitoneal
chemotherapy versus cytoreductive surgery alone for colorectal peritoneal
metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3
trial. Lancet Oncol. 2021; 22(2):256–266. DOI:
10.1016/S1470-2045(20)30599-4.
Article
38. Mendelaar PAJ, Smid M, van Riet J, Angus L, Labots M, Steeghs N, et al. Whole genome sequencing of metastatic colorectal cancer reveals
prior treatment effects and specific metastasis features. Nat Commun. 2021; 12:3269. DOI:
10.1038/s41467-021-23629-4. PMID:
34039979. PMCID:
PMC8155047.
40. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally
advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized
phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012; 30(16):1926–1933. DOI:
10.1200/JCO.2011.40.1836. PMID:
22529255.
Article
41. Piozzi GN, Kim SH. Robotic intersphincteric resection for low rectal cancer:
technical controversies and a systematic review on the perioperative,
oncological, and functional outcomes. Ann Coloproctol. 2021; 37(6):351–367. DOI:
10.3393/ac.2021.00836.0119. PMID:
34784706. PMCID:
PMC8717069.
Article
42. Eldamshety O, Kotb S, Khater A, Roshdy S, Elnahas W, Zahi MS, et al. Early and late functional outcomes of anal sphincter-sparing
procedures with total mesorectal excision for anorectal
adenocarcinoma. Ann Coloproctol. 2020; 36(3):148–154. DOI:
10.3393/ac.2018.07.19. PMID:
32311866. PMCID:
PMC7392569.
Article
43. Huh JW, Maeda K, Liu Z, Wang X, Roslani AC, Lee WY. Current status of “Watch-and-Wait” rectal cancer
treatment in Asia-Pacific countries. Ann Coloproctol. 2020; 36(2):70–77. DOI:
10.3393/ac.2020.01.19. PMID:
32054250. PMCID:
PMC7299564.
Article
44. Garcia-Aguilar J, Patil S, Kim JK, Yuval JB, Thompson H, Verheij F, et al. Preliminary results of the organ preservation of rectal
adenocarcinoma (OPRA) trial. J Clin Oncol. 2020; 38:4008. DOI:
10.1200/JCO.2020.38.15_suppl.4008.
Article
45. Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer
after a clinical complete response following neoadjuvant chemoradiation: a
systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017; 2(7):501–513. DOI:
10.1016/S2468-1253(17)30074-2.
Article
46. van der Valk MJM, Hilling DE, Bastiaannet E, Meershoek-Klein Kranenbarg E, Beets GL, Figueiredo NL, et al. Long-term outcomes of clinical complete responders after
neoadjuvant treatment for rectal cancer in the International Watch &
Wait Database (IWWD): an international multicentre registry
study. Lancet. 2018; 391(10139):2537–2545. DOI:
10.1016/S0140-6736(18)31078-X.
47. Kong JC, Guerra GR, Warrier SK, Ramsay RG, Heriot AG. Outcome and salvage surgery following "Watch and
Wait" for rectal cancer after neoadjuvant therapy: a systematic
review. Dis Colon Rectum. 2017; 60(3):335–345. DOI:
10.1097/DCR.0000000000000754. PMID:
28177997.
Article
48. Giunta EF, Bregni G, Pretta A, Deleporte A, Liberale G, Bali AM, et al. Total neoadjuvant therapy for rectal cancer: making sense of the
results from the RAPIDO and PRODIGE 23 trials. Cancer Treat Rev. 2021; 96:102177. DOI:
10.1016/j.ctrv.2021.102177. PMID:
33798955.
49. Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM, et al. RAPIDO collaborative investigators. Short-course radiotherapy
followed by chemotherapy before total mesorectal excision (TME) versus
preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in
locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3
trial. Lancet Oncol. 2021; 22(1):29–42. DOI:
10.1016/S1470-2045(20)30555-6.
50. Oh SG, Park IJ, Seo J, Kim YI, Lim SB, Kim CW, et al. Beware of early relapse in rectal cancer patients treated with
preoperative chemoradiotherapy. Ann Coloproctol. 2020; 36(6):382–389. DOI:
10.3393/ac.2020.06.11. PMID:
32674549. PMCID:
PMC7837400.
Article